Human obesity. ENOblock therapy inhibited gluconeogenesis, adiposity and obesity-related inflammation via concomitant repression in the
Human obesity. ENOblock therapy inhibited gluconeogenesis, adiposity and obesity-related inflammation via concomitant repression in the regulatory genes Pck-1, Srebp-1a and Srebp-1c, and Tnf-a and Il-6. These genetic alterations also made…